Use of miRNAs in Growth Hormone Deficiency (GHD)

Launched by UNIVERSITY OF PARMA · Jun 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of small molecules called miRNAs to help diagnose and treat Growth Hormone Deficiency (GHD) in children and young patients. GHD is a condition where the body does not produce enough growth hormone, which can lead to short stature and other growth issues. The goal of the study is to find new ways to identify GHD and to create personalized treatment plans that make the best use of resources, improve patient outcomes, and lower treatment costs.

If you have a child who is shorter than their peers and may have GHD, they could be eligible to participate in this trial. The study is looking for children with suspected GHD and those with confirmed GHD, as well as specific conditions like Noonan syndrome or Turner syndrome. Participants will be involved in tests that help researchers learn more about GHD and how best to treat it. The study is currently recruiting participants of all genders, aged between 2 and 15 years. It’s a chance for your child to contribute to important research that could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for aim 1:
• • Children with short stature and suspicion of GHD
• • Subjects with organic GH deficiency
• Exclusion criteria for aim 1:
• • -Subjects with underlying genetic conditions and chronic diseases
• Inclusion Criteria for aim 2-3-5:
• • patients having confirmed GHD enrolled for aim 1
• • patients with growth failure and born SGA (\>4 yr of age)
• • patients with Noonan and Turner syndrome and growth failure
• • patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure
• Inclusion Criteria for aim 4:
• • - Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy